A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

por Connor, Joseph P, Cristea, Mihaela C, Lewis, Nancy L, Lewis, Lionel D, Komarnitsky, Philip B, Mattiacci, Maria R, Felder, Mildred, Stewart, Sarah, Harter, Josephine, Henslee-Downey, Jean, Kramer, Daniel, Neugebauer, Roland, Stupp, Roger
Publicado 2013

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

por Camidge, D. Ross, Morgensztern, Daniel, Heist, Rebecca S., Barve, Minal, Vokes, Everett, Goldman, Jonathan W., Hong, David S., Bauer, Todd M., Strickler, John H., Angevin, Eric, Motwani, Monica, Parikh, Apurvasena, Sun, Zhaowen, Bach, Bruce Allen, Wu, Jun, Komarnitsky, Philip B., Kelly, Karen
Publicado 2021